Article | Published:

FBXL2- and PTPL1-mediated degradation of p110-free p85β regulatory subunit controls the PI(3)K signalling cascade

Nature Cell Biology volume 15, pages 472480 (2013) | Download Citation

Abstract

F-box proteins are the substrate-recognition subunits of SCF (Skp1/Cul1/F-box protein) ubiquitin ligase complexes. Purification of the F-box protein FBXL2 identified the PI(3)K regulatory subunit p85β and tyrosine phosphatase PTPL1 as interacting proteins. FBXL2 interacts with the pool of p85β that is free of p110 PI(3)K catalytic subunits and targets this pool for ubiquitylation and subsequent proteasomal degradation. FBXL2-mediated degradation of p85β is dependent on the integrity of its CaaX motif. Whereas most SCF substrates require phosphorylation to interact with their F-box proteins, phosphorylation of p85β on Tyr 655, which is adjacent to the degron, inhibits p85β binding to FBXL2. Dephosphorylation of phospho-Tyr-655 by PTPL1 stimulates p85β binding to and degradation through FBXL2. Finally, defects in the FBXL2-mediated degradation of p85β inhibit the binding of p110 subunits to IRS1, attenuate the PI(3)K signalling cascade and promote autophagy. We propose that FBXL2 and PTPL1 suppress p85β levels, preventing the inhibition of PI(3)K by an excess of free p85 that could compete with p85–p110 heterodimers for IRS1.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    & Function and regulation of cullin-RING ubiquitin ligases. Nat. Rev. Mol. Cell Biol. 6, 9–20 (2005).

  2. 2.

    , & SnapShot: F box proteins I. Cell 137, 1160–1161 (2009).

  3. 3.

    , , , & Box Proteins II. Cell 137, 1358 (2009).

  4. 4.

    et al. Identification of FBL2 as a geranylgeranylated cellular protein required for hepatitis C virus RNA replication. Mol. Cell 18, 425–434 (2005).

  5. 5.

    , , & Calmodulin antagonizes a calcium-activated SCF ubiquitin E3 ligase subunit, FBXL2, to regulate surfactant homeostasis. Mol. Cell Biol. 31, 1905–1920 (2011).

  6. 6.

    et al. F-box protein FBXL2 targets cyclin D2 for ubiquitination and degradation to inhibit leukemic cell proliferation. Blood 119, 3132–3141 (2012).

  7. 7.

    The phosphoinositide 3-kinase pathway. Science 296, 1655–1657 (2002).

  8. 8.

    et al. Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu. Rev. Cell Dev. Biol. 17, 615–675 (2001).

  9. 9.

    , , & The emerging mechanisms of isoform-specific PI3K signalling. Nat. Rev. Mol. Cell Biol. 11, 329–341 (2010).

  10. 10.

    , & The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat. Rev. Genet. 7, 606–619 (2006).

  11. 11.

    , , & A specific product of phosphatidylinositol 3-kinase directly activates the protein kinase Akt through its pleckstrin homology domain. Mol. Cell Biol. 17, 338–344 (1997).

  12. 12.

    , , & Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate. Science 275, 665–668 (1997).

  13. 13.

    , , & Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307, 1098–1101 (2005).

  14. 14.

    , , & PDK1, the master regulator of AGC kinase signal transduction. Semin. Cell Dev. Biol. 15, 161–170 (2004).

  15. 15.

    , , , & The p85 regulatory subunit of phosphoinositide 3-kinase down-regulates IRS-1 signalling via the formation of a sequestration complex. J. Cell Biol. 170, 455–464 (2005).

  16. 16.

    et al. Reduced expression of the murine p85α subunit of phosphoinositide 3-kinase improves insulin signalling and ameliorates diabetes. J. Clin. Invest. 109, 141–149 (2002).

  17. 17.

    , & Regulation of class IA PI3Ks: is there a role for monomeric PI3K subunits? Biochem. Soc. Trans. 35, 199–203 (2007).

  18. 18.

    et al. Hypoglycaemia, liver necrosis and perinatal death in mice lacking all isoforms of phosphoinositide 3-kinase p85α. Nat. Genet. 26, 379–382 (2000).

  19. 19.

    et al. Molecular balance between the regulatory and catalytic subunits of phosphoinositide 3-kinase regulates cell signalling and survival. Mol. Cell Biol. 22, 965–977 (2002).

  20. 20.

    & Proteomic analysis by multidimensional protein identification technology. Methods Mol. Biol. 328, 159–175 (2006).

  21. 21.

    , & Deconjugation of Nedd8 from Cul1 is directly regulated by Skp1-Fbox and substrate, and CSN inhibits deneddylated SCF by a non-catalytic mechanism. J. Biol. Chem. 287, 29679–29689 (2012).

  22. 22.

    et al. The regulatory subunits of PI3K, p85α and p85β, interact with XBP-1 and increase its nuclear translocation. Nat. Med. 16, 429–437 (2010).

  23. 23.

    & PTPL1: a large phosphatase with a split personality. Cancer Metast. Rev. 27, 205–214 (2008).

  24. 24.

    & A complex interplay between Akt, TSC2 and the two mTOR complexes. Biochem. Soc. Trans. 37, 217–222 (2009).

  25. 25.

    , , , & Rheb binds and regulates the mTOR kinase. Curr. Biol. 15, 702–713 (2005).

  26. 26.

    et al. Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signalling through downregulation of PDGFR. J. Clin. Invest. 112, 1223–1233 (2003).

  27. 27.

    , & mTOR: from growth signal integration to cancer, diabetes and ageing. Nat. Rev. Mol. Cell Biol. 12, 21–35 (2011).

  28. 28.

    et al. SH2 domains recognize specific phosphopeptide sequences. Cell 72, 767–778 (1993).

  29. 29.

    , & Regulation of the p85/p110α phosphatidylinositol 3’-kinase. Distinct roles for the n-terminal and c-terminal SH2 domains. J. Biol. Chem. 273, 30199–30203 (1998).

  30. 30.

    et al. Regulation of Class IA PI 3-kinases: C2 domain-iSH2 domain contacts inhibit p85/p110α and are disrupted in oncogenic p85 mutants. Proc. Natl Acad. Sci. USA 106, 20258–20263 (2009).

  31. 31.

    et al. Dynamics of the phosphoinositide 3-kinase p110delta interaction with p85α and membranes reveals aspects of regulation distinct from p110α. Structure 19, 1127–1137 (2011).

  32. 32.

    et al. Structure of lipid kinase p110β/p85β elucidates an unusual SH2-domain-mediated inhibitory mechanism. Mol. Cell 41, 567–578 (2011).

  33. 33.

    et al. p50α/p55α phosphoinositide 3-kinase knockout mice exhibit enhanced insulin sensitivity. Mol. Cell Biol. 24, 320–329 (2004).

  34. 34.

    et al. Increased insulin sensitivity and hypoglycaemia in micelacking the p85α subunit of phosphoinositide 3-kinase. Nat. Genet. 21, 230–235 (1999).

  35. 35.

    et al. Increased insulin sensitivity in mice lacking p85β subunit of phosphoinositide 3-kinase. Proc. Natl Acad. Sci. USA 99, 419–424 (2002).

  36. 36.

    & Dynamic steps in receptor tyrosine kinase mediated activation of class IA phosphoinositide 3-kinases (PI3K) captured by H/D exchange (HDX-MS). Adv. Biol. Regul. 53, 97–110 (2013).

  37. 37.

    , & Regulation of phosphoinositide 3-kinase expression in health and disease. Trends Biochem. Sci. 34, 115–127 (2009).

  38. 38.

    et al. Direct positive regulation of PTEN by the p85 subunitof phosphatidylinositol 3-kinase. Proc. Natl Acad. Sci. USA 107, 5471–5476 (2010).

  39. 39.

    , , & Increased p85/55/50 expression and decreased phosphotidylinositol 3-kinase activity in insulin-resistant human skeletal muscle. Diabetes 54, 2351–2359 (2005).

  40. 40.

    , , & Positive and negative regulation of phosphoinositide 3-kinase-dependent signalling pathways by three different gene products of the p85α regulatory subunit. Mol. Cell Biol. 20, 8035–8046 (2000).

  41. 41.

    et al. IRS-1 activates phosphatidylinositol 3’-kinase by associating with src homology 2 domains of p85. Proc. Natl Acad. Sci. USA 89, 10350–10354 (1992).

  42. 42.

    et al. Characterization of two 85 kd proteins that associate with receptor tyrosine kinases, middle-T/pp60c-src complexes, and PI3-kinase. Cell 65, 91–104 (1991).

  43. 43.

    et al. The putative tumour suppressor gene PTPN13/PTPL1 induces apoptosis through insulin receptor substrate-1 dephosphorylation. Cancer Res. 67, 6806–6813 (2007).

  44. 44.

    et al. Comparison of three directly coupled HPLC MS/MS strategies for identification of proteins from complex mixtures: single-dimension LCMS/MS, 2-phase MudPIT, and 3-phase MudPIT. Mass Spectrom 219, 245–251 (2002).

  45. 45.

    et al. An approach to correlate tandem mass spectral data of peptides with amino acid sequences in a protein database. J. Amer. Mass Spectrom 5, 976–989 (1994).

  46. 46.

    , & 3rd DTASelect and Contrast: tools for assembling and comparing protein identifications from shotgun proteomics. J. Proteome. Res. 1, 21–26 (2002).

  47. 47.

    et al. Refinements to label free proteome quantitation: how to deal with peptides shared by multiple proteins. Anal. Chem. 82, 2272–2281 (2010).

  48. 48.

    et al. SCF(Cyclin F) controls centrosome homeostasis and mitotic fidelity through CP110 degradation. Nature 466, 138–142 (2010).

  49. 49.

    et al. mTOR generates an auto-amplification loop by triggering theβTrCP- and CK1α-dependent degradation of DEPTOR. Mol. Cell 44, 317–324 (2011).

  50. 50.

    et al. Cyclin F-mediated degradation of ribonucleotide reductase M2 controls genome integrity and DNA repair. Cell 149, 1023–1034 (2012).

  51. 51.

    et al. FBXO11 targets BCL6 for degradation and is inactivated in diffuse large B-cell lymphomas. Nature 481, 90–93 (2012).

Download references

Acknowledgements

The authors thank J. Backer, J. H. Lee and R. K. Mallampalli for reagents, and J. Backer, J. R. Skaar and E. Skolnik for critical reading of the manuscript. M.P. is grateful to T. M. Thor for continuous support. This work was financially supported by grants from the National Institutes of Health (R01-GM057587, R37-CA076584 and R21-CA161108) to M.P. and a grant from Susan G. Komen for the Cure to S.D. A.S., L.F. and M.P.W. are supported by the Stowers Institute for Medical Research. M.P. is an Investigator with the Howard Hughes Medical Institute.

Author information

Author notes

    • Angelo Peschiaroli

    Present address: Centro Nazionale Ricerche, Institute of Cellular Biology and Neurobiology, Via E. Ramarini 32, 00015, Rome, Italy

Affiliations

  1. Department of Pathology, NYU Cancer Institute, New York University School of Medicine, 522 First Avenue, SRB 1107, New York, New York 10016, USA

    • Shafi Kuchay
    • , Shanshan Duan
    • , Emily Schenkein
    • , Angelo Peschiaroli
    •  & Michele Pagano
  2. Howard Hughes Medical Institute, USA

    • Shafi Kuchay
    •  & Michele Pagano
  3. The Stowers Institute for Medical Research, 1000 East 50th Street, Kansas City, Missouri 64110, USA

    • Anita Saraf
    • , Laurence Florens
    •  & Michael P. Washburn
  4. Department of Pathology and Laboratory Medicine, The University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, Kansas 66160, USA

    • Michael P. Washburn

Authors

  1. Search for Shafi Kuchay in:

  2. Search for Shanshan Duan in:

  3. Search for Emily Schenkein in:

  4. Search for Angelo Peschiaroli in:

  5. Search for Anita Saraf in:

  6. Search for Laurence Florens in:

  7. Search for Michael P. Washburn in:

  8. Search for Michele Pagano in:

Contributions

S.K. planned and performed most experiments and helped to write the manuscript. M.P. coordinated the study, oversaw the results, and wrote the manuscript. S.D., E.S. and A.P. helped with some experiments. A.S., L.F. and M.P.W. performed the mass spectrometry analysis of the FBXL2 complex purified by S.K. All authors discussed the results and commented on the manuscript.

Competing interests

The authors declare no competing financial interests.

Corresponding author

Correspondence to Michele Pagano.

Supplementary information

PDF files

  1. 1.

    Supplementary Information

    Supplementary Information

Excel files

  1. 1.

    Supplementary Information

    Supplementary Table 1

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/ncb2731